Medtronic's Hugo Surgical Robot Receives CE Mark for Advanced Vessel-Sealing Technology: A Game-Changer in Robotic Surgery
#MEDeviceBoston
Date: July 18, 2025
Estimated Read Time: 3 Minutes
Introduction
Medtronic just scored a big win in Europe with CE Mark approval for their LigaSure™ RAS vessel-sealing tech on the Hugo™ robotic surgery system. This is huge news for surgeons handling gynecologic, general, and urologic procedures—and a major milestone in Medtronic's robotics strategy.
The Power of LigaSure™ RAS Technology
What makes this LigaSure RAS technology so impressive? It brings Medtronic's trusted vessel-sealing capabilities to robotic surgery, handling vessels and thick tissue up to 7mm in diameter. The efficiency is remarkable—sealing vessels in just two seconds while minimizing thermal spread to surrounding tissue. This could mean shorter procedures and better outcomes for patients.
Running on the Valleylab™ FT10 energy platform, the LigaSure RAS Maryland instrument works seamlessly with the Hugo system, giving surgeons that extra precision they need during complex procedures.
Expanding Capabilities for Multiple Specialties
This CE Mark approval opens doors across several surgical areas:
- Gynecologic procedures: More precise tissue handling during hysterectomies
- Urologic procedures: Enhanced precision for prostatectomies
- General surgery: Advanced vessel sealing across various procedures
Matt Anderson from Medtronic's Surgical business put it well: "Today, with CE Mark for LigaSure RAS, Medtronic is fulfilling a promise to customers... This regulatory approval is a big step forward as we continue to shape the future of surgery."
The Hugo RAS System: A Growing Global Presence
Since getting its first CE Mark in October 2021, Hugo has been making waves globally and is now used in over 30 countries. The UK's National Health Service recently gave it a thumbs-up too.
What makes Hugo stand out? Its modular, multi-quadrant design offers flexibility across surgical approaches—a smart feature for hospitals looking to maximize their investment.
Looking Ahead: U.S. Market Entry and Future Developments
While European surgeons are already benefiting from Hugo with LigaSure, Medtronic is working on bringing this tech to the U.S. They submitted their FDA application for urology in Q1 2025, with plans to expand into hernia and gynecology.
CEO Geoff Martha has highlighted Hugo as key to improving growth in Medtronic's surgical business, noting that LigaSure is gaining strong adoption and market share.
The Bigger Picture: Transforming Surgical Care
This isn't just about a new product approval—it's about transforming surgical care. By combining advanced vessel-sealing with robotic precision, Medtronic aims to improve outcomes, boost efficiency, and potentially reduce recovery times.
As robotic surgery evolves, innovations like LigaSure RAS show how trusted surgical tools paired with cutting-edge robotics create new possibilities for surgeons and patients alike. With this approval, Medtronic takes another big step toward reshaping the future of surgery.
How MEDevice Boston Can Support Medtronic's Manufacturing Needs
MEDevice Boston (September 30-October 1, 2025) connects companies like Medtronic with specialized manufacturing partners essential for surgical robotics advancement. The event features suppliers offering precision components, advanced materials, quality systems, regulatory expertise, and supply chain solutions—all critical for technologies like LigaSure RAS. Beyond the exhibition floor, education sessions on regulations and market trends provide additional value for companies looking to enhance their innovation capabilities and manufacturing excellence.
